Member Info for Benharper

Yes, based on the Phase 1 trial data for AVA6000, it appears to have a longer **plasma elimination half-life** compared to conventional doxorubicin. The trial reported that released doxorubicin from AVA6000 had **a greater than 40% increase in plasma elimination half-life** versus conventional doxorubicin (historical data for 75 mg/m² dose). This suggests that AVA6000 provides a more sustained delivery of doxorubicin within the tumor while maintaining lower systemic exposure, which could reduce toxicities typically associated with conventional doxorubicin treatment.

I asked Co pilot to assess the abstract with regards to half life of dox compared to ava6000.

Read the abstract, it’s there now in black and white.

But but but, what about the half life..

Is that the sound of Eggy banging his head repeatedly on his desk?

Good for you, now does that mean we won’t hear from you between now and then?

Suggesting they have better data than ‘us’ is classic indisputable fud. F me, if that’s the case they why invest in anything. They will have reacted to November rns, and probably the slew of data we have since had is in part response to their decisions. No matter. We’ll see a bit more in the coming week. You let yourself down again there pubbore. You strive to sound neutral or at least considered but statements like that show your true colours.

A tiny bit of research revealed that fast track and accelerated approvals typically occurred during phase 2 of clinical development

14 years of over spend at the hands of the Tories.

I quote,

‘ It still amazes me how the clowns on here post their opinion as fact’

Lol

Good sea lion have a Mackerel.

The global doxorubicin market is projected to reach $1.7 billion by 2030.

what a **** poor response eggy, try again that was woeful.

Yep it’s a punt. Using a proven safer version of doxyrubicin in TNBC an indication that it’s used as first in line treatment. Professor Eggy strikes again

It’s at these conferences that the science meets it’s peers and business

I think 2 more clns until interim results. Agree with Har Chris with how to deal with next few months.

You have said that numerous times Eggy. The company themselves have said otherwise. I wonder who to believe?

Thanks Sandy,

So the 2 weekly arm broadens the utility and appeal of 6k.it did cause a delay but those hard yards are done now. Over the next few months we will hopefully reap the benefits.

Because of the 3+3 nature of P1a trials. The 2 week arm is only possible due to the remarkable safety profile of 6k. The reason for a 2 week arm we can only speculate. My guess is so that It can fit in with other chemo regimes.

Like I said Touk this is pointless. You’re a troll and not even a very good one. I recall being told in the animal models the ratio of dox released was 1:10, in humans is it’s more like 1:100. This is due to less fap in human plasma than mice plasma.

Yes after which we’ll get the results that some were inferring would be somehow late if they didn’t arrive next week!